Funding opportunities

Funding opportunities

If you know of any funding opportunities that may be of interest to our website visitors and you wish to have it included on this page please get in touch with Michael Hails in the TREAT-NMD coordination office.

Please note: information appearing below will be available until the advertised deadline, then it is automatically removed by our system.

Grant opportunity: MDF Genome Editing RFA

The Myotonic Dystrophy Foundation (MDF)
Closing Date: 30 Nov 2018

The Myotonic Dystrophy Foundation (MDF) is pleased to announce a Request for Applications (RFA) for the development of a genome editing strategy for Myotonic Dystrophy Type 1 (DM1). Through this RFA, MDF recognizes a need to advance genome editing technology and evaluate its potential as a therapy for use in DM1.

MDF intends to issue two 2-year awards of up to $250,000 total cost for projects that address the evaluation of genome editing strategies that target the DMPK gene. The focus of the RFA is on early stage discovery and development of in vivo genome editing technologies in academic laboratories or other nonprofit research institutions, utilizing state-of-the-art knowledge.  

Collaborations between experts in genome editing technologies and those with strong track records in Myotonic Dystrophy research are strongly encouraged. 

Applications are due November 30, 2018.

More information and the full RFA can be found on the MDF website



Muscular Dystrophy UK 2019 Grant Round

Muscular Dystrophy UK
Closing Date: 18 Jan 2019

The Muscular Dystrophy UK (MDUK) 2019 Grant Round is now open. Funding is offered for 4 year PhD studentships and project grants up to 3 years (including shorter, proof of concept projects of up to one year) that have relevance to one or more type of muscular dystrophy or a related neuromuscular condition.

Funding is available for research applications that can demonstrate relevance to Muscular Dystrophy UK’s goals and objectives. This includes research that increases understanding of the underlying causes and mechanisms of muscle-wasting conditions, develops and evaluates potential therapeutic approaches, addresses the impact of muscle-wasting conditions on the quality of life of patients and families, or establishes best practice in symptom management. Please see MDUK’s Research Strategy for more information. 

Whilst funding is only available for Principal Applicants who are based in the UK, international collaborations are strongly encouraged.

For more information please see the Muscular Dystrophy UK website or contact  

12 Apr 2017